Chan John K, Tewari Krishnansu S, Waller Sarah, Cheung Michael K, Shin Jacob Y, Osann Kathryn, Kapp Daniel S
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco School of Medicine, UCSF Helen Diller Family, Comprehensive Cancer Center, San Francisco, California 94143-1702, USA.
J Surg Oncol. 2008 Aug 1;98(2):111-6. doi: 10.1002/jso.21079.
To evaluate demographics, survival, and surgical trends for patients with malignant ovarian germ cell tumors.
SEER data abstracted from 1988 to 2001 and analyzed using Kaplan-Meier and Cox regression models.
Of 760 patients, the median age was 23 years. Seventy-six percent of patients presented with stage I-II disease, and 24% with stage III-IV. Fifty-five percent were immature teratomas, 32% dysgerminomas, and 13% yolk sac tumors. Fertility-preserving surgery was performed in 41.2% (n = 313) of patients. In those <45 years old, the use of fertility-preserving surgery increased from 40.5% to 44.5% to 48.4% over the time periods 1988-1992, 1993-1997, 1998-2001 (P = 0.25). The survival of patients who underwent fertility-preserving surgery was not statistically different compared to those who underwent standard surgery (P = 0.26). Patients with stage I-II disease had improved survival compared to stage III-IV disease (97.6% vs. 85.5%, P < 0.001). The overall survival of women with dysgerminomas, immature teratomas, and yolk sac tumors was 99.5%, 94.3%, and 85.4%, respectively (P < 0.001). In multivariate analysis, older age, advanced stage, and yolk sac tumor histology predicted for poorer survival.
Our data suggests that the use of fertility-preserving surgery with concomitant surgical staging for germ cell cancers has increased without compromising survival.
评估恶性卵巢生殖细胞肿瘤患者的人口统计学特征、生存率及手术趋势。
提取1988年至2001年的监测、流行病学与最终结果(SEER)数据,并使用Kaplan-Meier和Cox回归模型进行分析。
760例患者的中位年龄为23岁。76%的患者为Ⅰ-Ⅱ期疾病,24%为Ⅲ-Ⅳ期。55%为未成熟畸胎瘤,32%为无性细胞瘤,13%为卵黄囊瘤。41.2%(n = 313)的患者接受了保留生育功能手术。在年龄<45岁的患者中,1988 - 1992年、1993 - 1997年、1998 - 2001年期间保留生育功能手术的使用率从40.5%增至44.5%再增至48.4%(P = 0.25)。接受保留生育功能手术患者的生存率与接受标准手术患者相比无统计学差异(P = 0.26)。Ⅰ-Ⅱ期疾病患者的生存率高于Ⅲ-Ⅳ期疾病患者(97.6%对85.5%,P < 0.001)。无性细胞瘤、未成熟畸胎瘤和卵黄囊瘤女性患者的总生存率分别为99.5%、94.3%和85.4%(P < 0.001)。多因素分析显示,年龄较大、分期较晚和卵黄囊瘤组织学类型提示生存率较差。
我们的数据表明,对于生殖细胞癌采用保留生育功能手术并同时进行手术分期的情况有所增加,且未影响生存率。